ClinicalTrials.gg
CompletedNCT03233932Updated Jul 31, 2017

CKD-841 Pharmacokinetic/Pharmacodynamic Study

A Phase 1 interventional study of LeuplinⓡInj and CKD-841 in Postmenopausal Disorder, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-07-31.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Study summary

A randomized, open-label, single dose, parallel design phase I clinical trial to investigate the safety and pharmacokinetic/pharmacodynamics of CKD-841 or Leuplin Inj. 3.75mg after subcutaneous injection in postmenopausal female.

Read the detailed description

To investigate the safety and pharmacokinetic/pharmacodynamics of CKD-841 or Leuplinⓡ Inj. 3.75mg after subcutaneous injection in postmenopausal female is the purpose of this trial.

02

Conditions studied

  • Postmenopausal Disorder

Keywords

  • CKD-841
  • Leuplin
  • Postmenopausal
03

In context

Lead sponsor

Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy menopausal female
  • β-hCG is negative at screening and before administration of drug
  • Infertility by sterilization operation before 5 months from screening excluding ovarian cancer, uterine cancer etc...
  • Bwt ≥ 50Kg and (BMI) ≥ 18.5 and \< 25

Exclusion criteria

Exclusion Criteria:

  • History or current condition of disease related to Hepato-biliary system, renal system, nervous system, mental illness, immune system, respiratory system, endocrine system, hemato-oncology, circulatory system, musculoskeletal system or except for that, significant clinical disease
  • Uncontrolled diabetes mellitus
  • Pregnancy or breast feeding
  • History of taking medicine such as Leuprorelin acetate or similar affiliation drug within 12 weeks before administration of drug
  • Has to the active ingredient or or same affiliation drug of the investigational drug, hypersensitivity of a medicine contained gelatin especially
  • Has abnormal function of liver and kidney at screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Active comparator
    LeuplinⓡInj

    LeuplinⓡInj(=leuprorelin acetate 3.75mg)

    Drug: LeuplinⓡInj

  • Experimental
    CKD-841

    CKD-841(=leuprorelin acetate 3.75mg)

    Drug: CKD-841

Interventions

  • DrugLeuplinⓡInj

    Investigational drug(=LeuplinⓡInj)is prescribed single injection dose by subcutaneous to 6 of randomized subjects once.

  • Investigational drug(=CDK-841) is prescribed single injection dose by subcutaneous to 6 of randomized subjects once.

06

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax) of Leuprorelin

    Peak Plasma Concentration (Cmax) in ng/mL

    Time frame: From before injection to up to 1008 hours post injection

  2. Area Under the plasma drug Concentration-time curve to last measurement (AUClast ) of Leuprorelin

    Area Under the plasma drug Concentration-time curve to last measurement (AUClast ) in ng•hr/mL

    Time frame: From before injection to up to 1008 hours post injection

  3. Area Under the plasma drug Concentration-time curve extrapolated to infinity (AUCinf) of Leuprorelin

    Area Under the plasma drug Concentration-time curve extrapolated to infinity (AUCinf) in ng•hr/mL

    Time frame: From before injection to up to 1008 hours post injection

  4. Area Under the plasma drug Concentration-time curve from 7 day to last measurement (AUC7-t) of Leuprorelin

    Area Under the plasma drug Concentration-time curve from 7 day to last measurement (AUC7-t) in ng•hr/mL

    Time frame: From before injection to up to 1008 hours post injection

  5. The time -to-maximal serum or plasma concentrations (Tmax) of Leuprorelin

    The time -to-maximal serum or plasma concentrations (Tmax) in hr

    Time frame: From before injection to up to 1008 hours post injection

  6. Terminal half-life (t1/2) Luteinizing Hormone(LH) of Leuprorelin

    Terminal half-life (t1/2) Luteinizing Hormone(LH) in IU/L

    Time frame: From before injection to up to 1008 hours post injection

  7. Follicular Stimulating Hormone(FSH) of Leuprorelin

    Follicular Stimulating Hormone(FSH) in IU/L

    Time frame: From before injection to up to 1008 hours post injection

  8. Estradiol of Leuprorelin

    Estradiol in pg/ml

    Time frame: From before injection to up to 1008 hours post injection

Secondary outcomes

  1. Safety Assessment by evaluating adverse events(AEs).

    Assessment of the safety of subjects by evaluating adverse events(AEs).

    Time frame: From day1 to day 56

07

Study locations

1 site
  • Severance Hospital
    Seoul, Yonsei-ro, Seodaemun-gu 50-1 03722, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2016 to primary completion in Jul 2017, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2016
First posted
Jul 31, 2017
StartActual
Apr 2016
Primary completionActual
Jul 2017
CompletionActual
Jul 2017
Last update
Jul 31, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03233932
Collaborators
Severance Hospital
Responsible party
Sponsor
First posted
Jul 31, 2017
Start date
Apr 2016
Primary completion
Jul 2017
Completion
Jul 2017
Last update
Jul 31, 2017

Study contacts

Min Soo Park, Ph.D
principal investigator · Severance Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide

Start the discussion